Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ICER's Ambitious 2018 Review Agenda Takes On Groundbreaking Treatments

10 Aug 2017

• By Cathy Kelly

Related Content

ICER Eyes Gene Therapy: Category-wide Policy In Works As Spark Moves To Approval

05 Jul 2017

Loxo Sees Larotrectinib As Model Form Of Oncology Drug Development

05 Jun 2017

Kite On Course For FDA Filing On Positive CAR-T Durability Data

01 Mar 2017

Momentum Builds For Tomorrow's More Convenient Hemophilia Drugs

13 Jul 2017

Novartis' CAR-T Poised For The Market After Unanimous FDA Adcomm Review

13 Jul 2017

Teva Clinches Third Place In CGRP Race With A Phase III Migraine Win

31 May 2017

Related Companies

Spark Therapeutics, Inc.

Novartis AG

Kite Pharma, Inc.

Johnson & Johnson

Pfizer Inc.

Opko Health

Roche Holding AG

Bayer AG

Amgen, Inc.

Eli Lilly and Company

Teva Pharmaceutical Industries Ltd.

Loxo Oncology at Lilly

Vertex Pharmaceuticals Incorporated

Additional Topics

US States Pricing Strategies Reimbursement

More from Pricing Debate

More from Market Access

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.